A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity
- 1 January 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hypertension
- Vol. 25 (1), 63-72
- https://doi.org/10.1097/hjh.0b013e32800ff5d6
Abstract
Despite the availability of efficacious drugs, the success of treating hypertension is limited by patients' inconsistent drug intake. Immunization against angiotensin II may offer a valuable alternative to conventional drugs for the treatment of hypertension, because vaccines induce relatively long-lasting effects and do not require daily dosing. Here we describe the preclinical development and the phase I clinical trial testing of a virus-like particle (VLP)-based antihypertensive vaccine. An angiotensin II-derived peptide was conjugated to the VLP Qβ (AngQb). AngQb was highly immunogenic in mice and rats. To test for efficacy, spontaneously hypertensive rats (SHR) were immunized with 400 μg AngQb or VLP alone. Group mean systolic blood pressure (SBP) was reduced by up to 21 mmHg (159 ± 2 versus 180 ± 5 mmHg, P Conclusions AngQb reduces blood pressure in SHR to levels obtained with an ACE inhibitor, and is immunogenic and well tolerated in humans. Therefore, vaccination against angiotensin II has the potential to become a useful antihypertensive treatment providing long-lasting effects and improving patient compliance.Keywords
This publication has 26 references indexed in Scilit:
- Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjectsClinical Science, 2004
- Renin–angiotensin vaccine: old story, new project ‘efficacy versus safety’Clinical Science, 2004
- Worldwide prevalence of hypertensionJournal of Hypertension, 2004
- Therapeutic vaccination to block receptor–ligand interactionsExpert Opinion on Biological Therapy, 2003
- The Economic Impact of HypertensionThe Journal of Clinical Hypertension, 2003
- A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responsesVaccine, 2002
- Virus-Like Particles as a Modular System for Novel VaccinesIntervirology, 2002
- Long-term compliance with antihypertensive therapyBlood Pressure Monitoring, 2000
- Immunologic approaches to blockade of the renin-angiotensin system: A reviewAmerican Heart Journal, 1989
- Studies on the role of angiotensin in experimental renovascular hypertension: an immunologic approachJCI Insight, 1969